Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5721994 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2867683 | 1.00 | — | — | |
| SCHEMBL29455057 | 0.97 | — | — | |
| SCHEMBL19628 | 0.97 | — | — | |
| Bromide SCHEMBL27489538 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL15387433 | 0.94 | — | — | |
| Bromide SCHEMBL30665091 | 0.94 | — | — | |
| SCHEMBL28202174 | 0.94 | — | — | |
| SCHEMBL28007338 | 0.94 | — | — | |
| Bromide SCHEMBL10383564 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | claimed |
| CN-119161296-A | Continuous flow synthesis process of 2-chloro-3-aminopyridine | 上海惠和化德生物科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| WO-2024153856-A1 | PROCESS FOR THE PREPARATION OF 3-(4,5-DICHLORO-2-(4-(TRIFLUOROMETHOXY)PHENOXY)BENZAMIDO)PYRIDINE 1-OXIDE | ORION CORPORATION (FI) | 2024-07-25 | — | — | WO | claimed |
| CN-117903047-A | Method for synthesizing 3-amino-2-chloropyridine by micro-channel continuous flow | 湖北泰盛化工有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-116554091-A | Synthesis method of 2-chloro-3-aminopyridine chlorination catalyst | 铜仁贵江科技有限责任公司 | 2023-08-08 | — | — | CN | claimed |
| CN-101302190-B | Method for preparing 2,3-dichloropyridine | Hebei yanuo chemical industry co ltd | 2011-07-27 | — | — | CN | claimed |
| CN-1910152-B | Process for the manufacture of 2,3-dichloropyridine | DU PONT | 2010-07-21 | — | — | CN | claimed |
| EP-2155152-A2 | COLOURING COMPOSITION COMPRISING AN AMINOPYRAZOLOPYRIDINE OXIDATION BASE AND EXHIBITING AN ACIDIC PH | L'Oreal (FR) | 2010-02-24 | — | — | EP | claimed |
| EP-2114901-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | Tibotec Pharmaceuticals (IE) | 2009-11-11 | — | — | EP | claimed |
| WO-2008138845-A2 | COLOURING COMPOSITION COMPRISING AN AMINOPYRAZOLOPYRIDINE OXIDATION BASE AND EXHIBITING AN ACIDIC PH | L'OREAL (FR) | 2008-11-20 | — | — | WO | claimed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | claimed |
| US-20070161797-A1 | Process for the manufacture of 2,3-dichloropyridine | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-07-12 | — | — | US | claimed |
| CN-1910152-A | Process for the manufacture of 2,3-dichloropyridine | DU PONT (US) | 2007-02-07 | — | — | CN | claimed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | claimed |
| EP-1706381-A2 | PROCESS FOR THE MANUFACTURE OF 2,3-DICHLOROPYRIDINE | E.I.Du pont de nemours and company (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005070888-A2 | PROCESS FOR THE MANUFACTURE OF 2,3-DICHLOROPYRIDINE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1267872-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | claimed |
| EP-1261342-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-04 | — | — | EP | claimed |
| WO-2001064218-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |
| WO-2001064197-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |